NCT04514419进行中（未招募）3 期
A Phase III Study to Compare HS627 vs. Pertuzumab on the Efficacy, Safety and Immunogenicity in Combination With Trastuzumab and Docetaxel as Neoadjuvant Therapy in Patients With Early-stage or Locally Advanced HER2 Positive Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 408
- 试验地点
- 1
- 主要终点
- Percentage of participants achieving Pathological Complete Response (pCR) as Assessed by the Independent Review Committee (IRC)
研究概览
简要总结
The trial included screening period (4 weeks) and treatment period (4 treatment cycles, at least 12 weeks).
详细描述
A multicenter, randomized, double-blind, positive drug parallel control design was used. The trial included screening period (4 weeks) and treatment period (4 treatment cycles, at least 12 weeks). All eligible subjects were randomly divided into experimental group (hs627 treatment group) and control group (pertuzumab) treatment group. After 4 treatment cycles, the subjects arranged surgical treatment, and then conducted the last visit.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed invasive breast carcinoma with a primary tumor size of more than (>) 2 centimeters (cm) by standard local assessment technique；
- •Breast cancer stage at presentation: early-stage (T2-3, N0-1, M0), locally advanced (T2-3, N2-3,M0 or T4a-c, any N, M0), or infl ammatory (T4d, any N,M0)；
- •Known hormone receptor status (estrogen receptor and/or progesterone receptor)；
- •HER2 positive (HER2+++ by IHC or ISH+).
- •Baseline left ventricular ejection fracture >= 55% measured by echocardiography (preferred) or multiple gated acquisition scan；
- •Normalities in liver, kidney or hematologic function laboratory tests immediately prior to randomization;
- •Absolute value of neutrophils ≥ 1.5 × 109 / L;
- •Platelet ≥ 90×109 / L;
- •Hemoglobin ≥ 90g / L;
- •Serum creatinine≤ 1.5 times the upper limit of normal (ULN);
- •Serum total bilirubin≤1.5 times ULN (except for Gilbert syndrome);
- •Aspartate aminotransferase (AST) and / or alanine aminotransferase (ALT) ≤ 1.5-fold ULN;
- •International normalized ratio (INR), activated partial prothrombin time (APTT) ≤ 1.5 times ULN.
排除标准
- •Stage IV metastatic ;
- •Bilateral breast cancer;
- •Previous anti-cancer therapy or radiotherapy for any malignancy;
- •History of other malignancy within 5 years, except for appropriately-treated carcinoma in Cervical carcinoma in situ, basal cell carcinoma or squamous cell skin cancer;
- •Serious cardiac illness or medical condition;
- •HIV antibody positive; HCV antibody positive and HCV RNA positive; HBcAb or HBsAg positive, and HBV DNA positive;
- •Sensitivity to any of the study medications, any of the ingredients or excipients of these medications;
- •Known mental history had poor compliance;
- •Known to have drug abusers;
- •Concurrent anti-cancer treatment in another investigational trial, including hormone therapy, bisphosphonate therapy, or immunotherapy;
- •Needed intravenous antibiotic treatment due to infection within 7 days before random enrollment;
- •Major surgical procedure unrelated to breast cancer within 4 weeks prior to randomization or expected to perform major surgery during the trial period;
- •Premenopausal women (menopause is defined as non treatment induced menopause≥12 months) or without surgical sterilization (e.g., ovariectomy and / or uterus): refuse to take one or more effective contraceptive measures during treatment and at least 6 months after the last study treatment; blood pregnancy test is positive; pregnant or lactating women; Considered unsuitable for the study or may not be able to complete the trial due to other reasons.
研究组 & 干预措施
Trastuzumab + HS627 + Docetaxel
Experimental
Trastuzumab HS627 Docetaxel
干预措施: HS627 (Drug)
Trastuzumab + Pertuzumab + Docetaxel
Experimental
Trastuzumab Pertuzumab Docetaxel
干预措施: Pertuzumab (Drug)
结局指标
主要结局
Percentage of participants achieving Pathological Complete Response (pCR) as Assessed by the Independent Review Committee (IRC)
时间窗: After surgery (At surgery cycle 4 Days 22-35)(1 cycle = 21 days)
pCR was defined as ypT0/is According to the American Joint Committee on Cancer Staging System as Assessed by the IRC
次要结局
- Percentage of Participants With Total Pathologic Complete Response (tpCR) as Assessed by the Independent Review Committee (IRC)(After surgery (At surgery cycle 4 Days 22-35) (1 cycle = 21 days))
- Percentage of Participants With pCR as Assessed by the Local Pathologist(After surgery (At surgery cycle 4 Days 22-35) (1 cycle = 21 days))
- Percentage of Participants With Total Pathologic Complete Response (tpCR) as Assessed by the Local Pathologist(After surgery (At surgery cycle 4 Days 22-35) (1 cycle = 21 days))
- Percentage of Participants with vital signs, physical examination, left ventricular ejection fraction (LVEF), laboratory examination, adverse events (AE) until last visit(Last Visit （After surgery 8 days）（After 4 cycles treatment ，After surgery ） (1 cycle = 21 days))
- Percentage of Participants With an Objective Response(Prior to surgery (Cycle 4 Days 21) (1 cycle = 21 days))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate CancerNCT05730712Mayo Clinic7
已完成
3 期
Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast CancerBreast CancerNCT00615602Hellenic Oncology Research Group489
已完成
3 期
Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal CancerMetastatic Colorectal CancerNCT00252564US Oncology Research247
已完成
3 期
Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast CancerStage IV Breast CancerBreast CancerNCT00146549Dana-Farber Cancer Institute250
Unknown
4 期
Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus AlogliptinType 2 Diabetes MellitusNCT02426294Pusan National University Hospital154